Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Targeting Metabolic Disorders With Advinus Deal

This article was originally published in PharmAsia News

Executive Summary

Merck is targeting metabolic disorders in a research-based collaboration deal with Bangalore, India-based Advinus Therapeutics

You may also be interested in...



Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal

MUMBAI - Past debacles in the glucokinase class of compounds notwithstanding, India's leading research firm Advinus Therapeutics has announced that it has discovered a novel molecule - coded GKM-001 - for the treatment of type 2 diabetes

Advinus Bets On Novel Glucokinase, Claiming Advantages Over Peer Compounds As It Scans For Out-licensing Deal

MUMBAI - Past debacles in the glucokinase class of compounds notwithstanding, India's leading research firm Advinus Therapeutics has announced that it has discovered a novel molecule - coded GKM-001 - for the treatment of type 2 diabetes

J&J Teams With Advinus For Drug Discovery In India

NEW DELHI - India's Tata Group company Advinus has formed a drug discovery and early clinical development tie-up with Ortho-McNeil-Janssen Pharmaceuticals, an arm of U.S.-based Johnson & Johnson

Related Content

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel